AUTHORS
Gaurav Bedse, PhD, Shaun Kumar2, Daniel Parra Gonzalez3, Jalaja Potluri, MD4, Rajeev Menon, PhD5, Benjamin Engelhardt6, Jiuhong Zha, PhD7
AFFILIATIONS
1 AbbVie Inc, North Chicago, Illinois, United States
2 Parexel International, Raleigh, United States
3 Parexel International, Raleigh, United States
4 AbbVie Inc, North Chicago, Illinois, United States
5 AbbVie Inc, North Chicago, Illinois, United States
6 AbbVie Deutschland GmbH & Co. KG, Ludwigshafen am Rhein, Germany
7 AbbVie Inc, North Chicago, Illinois, United States
ABSTRACT
Introduction: Pivekimab sunirine (PVEK) is a CD123-targeted antibody-drug conjugate (ADC) comprised of an anti-CD123 monoclonal immunoglobulin G1 (IgG1) antibody conjugated via a cleavable linker to an indolinobenzodiazepine pseudodimer (IGN) payload FGN849. IGN induces single-strand DNA breaks through alkylation, which induces cell death. PVEK is the first-in-class and only ADC FDA-approved for adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and can be initiated in an outpatient setting. Here, we present the clinical pharmacokinetics and exposure-response (E-R) relationships for PVEK monotherapy that supported the recommended PVEK selection of 0.045 mg/kg administered every 3 weeks (Q3W).
Methods: PVEK was administered intravenously in the CADENZA trial (NCT03386513) across two schedules: 0.015–0.45 mg/kg Q3W and fractionated dosing (0.015–0.06 mg/kg) on Days 1, 4, and 8 Q3W. Dose escalation and expansion cohorts mainly included CD123-positive patients with relapsed/refractory (R/R) AML and R/R or frontline BPDCN. Pharmacokinetic (PK) data were analyzed by non-compartmental analysis (Phoenix® WinNonlin® 8.3) and modeled by an integrated population PK (pop-PK) model for PVEK (ADC), total antibody (TAb), and payload (NONMEM 7.4.4). Exposure metrics derived from the pop-PK model (Cycle 1 maximum concentration [Cmax,C1], Cycle 1 average concentration [Cavg,C1], and Cavg up to the time of event [Cavg,TE]) for PVEK (ADC) and unconjugated payload FGN849 were examined using exposure-quartile plots and logistic regression analyses. Key efficacy and safety endpoints examined in E-R analyses were composite complete remission (complete response [CR]+ clinical complete response [CRc]), Grade ≥2 infusion-related reactions (IRR), and Grade ≥3 infections.
Results: PVEK (ADC) and total antibody (TAb) exhibited greater-than-dose-proportional PK in the lower dose range of 0.045–0.18 mg/kg Q3W, including the recommended dose, consistent with target-mediated drug disposition. Dose-proportional PK was observed at higher doses (0.18–0.45 mg/kg Q3W). ADC and FGN849 exposures were comparable between CD123-positive AML and BPDCN patients at 0.045 mg/kg Q3W. The pop-PK model adequately characterized CADENZA PK data (N=175), with an estimated ADC clearance of 1.78 L/h (between-subject variability: 84%).
Exposure-efficacy analyses demonstrated that frontline BPDCN patients achieving CR+CRc had a higher median PVEK Cavg,C1 and Cmax,C1 than those who did not (N=33). A consistent trend of higher ADC exposures (Cavg,C1) was also observed in R/R BPDCN patients (N= 50) who achieved CR+ CRc versus those who did not. Exposure-safety analyses on data from all patients in CADENZA across doses of 0.015–0.45 mg/kg (N=176) identified significant positive associations between FGN849 exposure and both Grade ≥2 IRR and Grade ≥3 infections, informing the benefit-risk profile at the recommended dose.
Conclusions: Integrated clinical PK and E-R analyses from the CADENZA trial support 0.045 mg/kg Q3W as the recommended dose for PVEK monotherapy in adult BPDCN patients, balancing meaningful clinical efficacy and an acceptable safety profile.
DISCLOSURES
Gaurav Bedse, PhD: AbbVie Inc - Current equity holder in publicly-traded company; AbbVie Inc - Divested equity in a private or publicly-traded company in the past 24 months; AbbVie Inc - Current Employment